Glioblastoma multiforme (GBM) is now defined by the WHO 2021 as a diffuse astrocytic glioma with no mutations in IDH genes or histone H3 genes. It is the most common primary brain tumor in humans. Like other astrocytomas, GBM originates from astrocytes, a type of glial cells that are non-neuronal and function to provide structural and biochemical support to the brain’s neuronal network. GBM continues to be a disease with some of the highest unmet needs in oncology, with patients having a median overall survival (OS) of between one and two years. The lack of therapies is primarily due to the inability of drugs to penetrate the blood-brain barrier (BBB).
The market of GBM relies predominantly on temozolomide and bevacizumab, which accounted for 46% and 51%, respectively, of the total $549.1M sales in 2020. For this market to witness true growth, the currently marketed products would need to be almost entirely replaced by new pipeline products, owing to the significant presence of generic temozolomide and the introduction of bevacizumab biosimilars. However, a high failure rate has been historically observed for late-stage GBM trials and may impact the pipeline forecast and impede the market growth. Nevertheless, eight pipeline agents are expected to enter the 8MM and drive the GBM growth to $868.5M by 2030 at a Compound Annual Growth Rate (CAGR) of 4.7%.
KEY QUESTIONS ANSWERED
Eight Phase II-III pipeline agents are expected to enter the Glioblastoma market from 2024 onwards. What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
What are the current unmet needs in GBM, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy?
What is the expected future uptake of protein kinase inhibitors across the 8MM?
Overview of Glioblastoma Multiforme including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Topline Glioblastoma Multiforme market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting Glioblastoma Multiforme therapeutics sales in the 8MM.
Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II – III).
Analysis of the current and future market competition in the global Glioblastoma Multiforme therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
The main drivers of growth include the anticipated approval and launch of eight pipeline agents during the forecast period, of which cancer vaccines and protein kinase inhibitors are the dominating classes.
The primary barrier to growth in the forecast period will be the high failure rates historically observed for Phase III GBM trials, impacting the pipeline forecast. The high genericization of temozolomide and recent patent expiration of Avastin, leading to biosimilar entry, also reduces the Glioblastoma Multiforme (GBM) market potential.
DCVax-L, regorafenib, and paxalisib are the three pipeline agents expected to generate the highest sales for GBM from 2020-2030.
Aside from improving OS, other key unmet needs in the GBM market include; Predictive biomarkers to guide personalized therapy and the need to find more efficacious treatment in O6-methylguanine-DNA methyltransferase (MGMT) unmethylated patients who typically have a poor response to temozolomide.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
Develop business strategies by understanding the trends shaping and driving the global Glioblastoma Multiforme therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Glioblastoma Multiforme market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global Glioblastoma Multiforme therapeutics market from 2020-2030.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Merck & Co
Heritage Pharmaceuticals (Emcure)
Nipro ES Pharma
Epitopoietic Research Corporation
Table of Contents
| List of Tables
| List of Figures
| About GlobalData
1 Glioblastoma Multiforme: Executive Summary
1.1 The Glioblastoma Multiforme Market is Forecast to Reach $868.5M by 2030 Across the 8MM
1.2 GBM-AGILE Candidates Set to Penetrate the Market While Merck & Co. Expands its Early-Stage Portfolio and Roche Experiences Erosion
1.3 High Unmet Needs Exist in the GBM Market, Especially in MGMT-Promoter Unmethylated Patients and Unresectable Patients
1.4 Opportunities for New Entrants with Better Markers of Prognosis and Drug Targets
1.5 Novel GBM-AGILE Drug Candidates and Immunotherapies Expected to Launch During the Forecast Period
1.6 What Do Physicians Think?
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.2 Classification or Staging Systems
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 8MM Forecast Methodology
4.4.2 Forecast Assumptions and Methods
4.4.3 Diagnosed Incident Cases of Brain Cancer
4.4.4 Diagnosed Incident Cases of Brain Cancer by Type
4.4.5 Diagnosed Incident Cases of Glioblastoma by Grade
4.4.6 Diagnosed Incident Cases of Glioblastoma by Origin
4.4.7 Diagnosed Incident Cases of Glioblastoma by Biomarkers
4.4.8 Diagnosed Incident Cases of Glioblastoma by Mutations
4.4.9 Five-Year Diagnosed Prevalent Cases of Brain Cancer
4.5.1 Epidemiological Forecast Insight
4.5.2 COVID-19 Impact
4.6 Epidemiological Forecast for Brain Cancer (2020–2030)
4.6.1 Diagnosed Incident Cases of Brain Cancer
4.6.2 Age-Specific Diagnosed Incident Cases of Brain Cancer
4.6.3 Sex-Specific Diagnosed Incident Cases of Brain Cancer
4.6.4 Diagnosed Incident Cases of Brain Cancer by Type
4.6.5 Diagnosed Incident Cases of Glioblastoma by Grade
4.6.6 Diagnosed Incident Cases of Glioblastoma by Origin
4.6.7 Diagnosed Incident Cases of Glioblastoma by Biomarkers
4.6.8 Diagnosed Incident Cases of Glioblastoma by Mutations
4.6.9 Five-Year Diagnosed Prevalent Cases of Brain Cancer
4.6.10 Limitations of the Analysis
4.6.11 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 KOL Insights on Disease Management
6 Current Treatment Options
7 Unmet Needs and Opportunity Assessment
7.2 Identification and Validation of Biomarkers and Drug Targets
7.3 Overcoming the Blood-Brain Barrier to Improve the Efficacy of Treatments
7.4 Better Treatment Options for MGMT Unmethylated and Unresectable Patients
7.5 Differentiating Pseudoprogression and True Progression
9 R&D Strategies
9.1.1 The Efficacy of Immunotherapy in GBM
9.1.2 Predictive Biomarkers and Targeted Therapy
9.1.3 Improving Therapy Administration Routes
9.2 Clinical Trials Design
9.2.1 Clinical Endpoints
9.2.2 More Umbrella or Platform Trial Designs
9.2.3 Comparator Arms
10 Pipeline Assessment
10.2 Promising Drugs in Clinical Development
11 Pipeline Valuation Analysis
11.2 Competitive Assessment
12 Current and Future Players
12.2 Deal-Making Trends
13 Market Outlook
13.1 Global Markets
13.1.2 Drivers and Barriers – Global Issues
13.2.2 Key Events
13.2.3 Drivers and Barriers
13.3.2 Key Events
13.3.3 Drivers and Barriers
13.4.2 Key Events
13.4.3 Drivers and Barriers
13.5.2 Key Events
13.5.3 Drivers and Barriers
14.3.1 Forecasting Methodology
14.4 Primary Research – KOLs Interviewed for This Report
14.5 Primary Research – Prescriber Survey
14.6 About the Authors
14.6.2 Therapy Area Director
14.6.4 Managing Epidemiologist
14.6.5 Global Director of Therapy Analysis and Epidemiology
14.6.6 Global Head and EVP of Healthcare Operations and Strategy
14.1 Contact Us
List of Tables
Table 1: Glioblastoma Multiforme: Key Metrics in the 8MM
Table 2: Classification of Key Gliomas and Corresponding Diagnostic Genes
Table 3: Risk Factors and Comorbid Conditions Associated with Brain Cancer
Table 4: Treatment Guidelines for GBM
Table 5: Top 10 Deals by Value, 2019–2021
Table 6: GBM Market – Global Drivers and Barriers, 2020–2030
Table 7: Key Events Impacting Sales for GBM in the US, 2020–2030
Table 8: GBM Market – Drivers and Barriers in the US, 2020–2030
Table 9: Key Events Impacting Sales for GBM in the 5EU, 2020–2030
Table 10: GBM Market – Drivers and Barriers in the 5EU, 2020–2030
Table 11: Key Events Impacting Sales for GBM in Japan, 2020–2030
Table 12: GBM Market – Drivers and Barriers in Japan, 2020–2030
Table 13: Key Events Impacting Sales for GBM in China, 2020–2030
Table 14: GBM Market – Drivers and Barriers in China, 2020–2030
Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global (8MM) Sales Forecast by Country for GBM in 2020 and 2030
Figure 2: Analysis of the Company Portfolio Gap in GBM During the Forecast Period, 2020–2030
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Recurrent GBM During the Forecast Period
Figure 4: Genetic and Molecular Pathogenesis of GBM
Figure 5: 8MM, Diagnosed Incidence of Brain Cancer, Men, Cases Per 100,000 Population All Ages, 2010–2030
Figure 6: 8MM, Diagnosed Incidence of Brain Cancer, Women, Cases Per 100,000 Population All Ages, 2010–2030
Figure 7: 8MM, Sources Used to Forecast Diagnosed Incident Cases Brain Cancer (ICD-10 = C70, C71, C72)
Figure 8: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of Brain Cancer (ICD-10 = C70, C71, C72)
Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Brain Cancer (ICD-10 = C70, C71, C72) by Type
Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Glioblastoma by Grade (WHO Grading System)
Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Glioblastoma by Origin
Figure 12: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Glioblastoma by Biomarkers and Mutations
Figure 13: 8MM, Diagnosed Incident Cases of Brain Cancer, N, Both Sexes, All Ages, 2020
Figure 14: 8MM, Diagnosed Incident Cases of Brain Cancer by Age, N, Both Sexes, 2020
Figure 15: 8MM, Diagnosed Incident Cases of Brain Cancer by Sex, N, All Ages, 2020
Figure 16: 8MM, Diagnosed Prevalent Cases of Brain Cancer by Type, N, Both Sexes, All Ages, 2020
Figure 17: 8MM, Diagnosed Incident Cases of Glioblastoma by Grade, N, Both Sexes, All Ages, 2020
Figure 18: 8MM, Diagnosed Incident Cases of Glioblastoma by Origin, N, Both Sexes, All Ages, 2020
Figure 19: 8MM, Diagnosed Prevalent Cases of Glioblastoma by Biomarkers, N, Both Sexes, All Ages, 2020
Figure 20: 8MM, Diagnosed Prevalent Cases of Glioblastoma by Mutations, N, Both Sexes, All Ages, 2020
Figure 21: 8MM, Five-Year Diagnosed Prevalent Cases of Brain Cancer, N, Both Sexes, All Ages, 2020
Figure 22: Overview of the Treatment Algorithm in GBM
Figure 23: Unmet Needs and Opportunities in GBM
Figure 24: Overview of the Development Pipeline in GBM
Figure 25: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for GBM in the 8MM During the Forecast Period
Figure 26: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Temodar, in Newly Diagnosed GBM
Figure 27: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Gleostine, in Recurrent GBM
Figure 28: Analysis of the Company Portfolio Gap in GBM During the Forecast Period
Figure 29: Global (8MM) Sales Forecast by Country for GBM in 2020 and 2030
Figure 30: Sales Forecast by Class for GBM in the US in 2020 and 2030
Figure 31: Sales Forecast by Class for GBM in the 5EU in 2020 and 2030
Figure 32: Sales Forecast by Class for GBM in Japan in 2020 and 2030
Figure 33: Sales Forecast by Class for GBM in China in 2020 and 2030
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.